APA (7th ed.) Citation

Cortes, J. E., Gambacorti-Passerini, C., Deininger, M. W., Mauro, M. J., Chuah, C., Kim, D., . . . Brümmendorf, T. H. (2018). Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. Journal of clinical oncology, 36(3), 231-237. https://doi.org/10.1200/JCO.2017.74.7162

Chicago Style (17th ed.) Citation

Cortes, Jorge E., et al. "Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial." Journal of Clinical Oncology 36, no. 3 (2018): 231-237. https://doi.org/10.1200/JCO.2017.74.7162.

MLA (9th ed.) Citation

Cortes, Jorge E., et al. "Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial." Journal of Clinical Oncology, vol. 36, no. 3, 2018, pp. 231-237, https://doi.org/10.1200/JCO.2017.74.7162.